Pharmacokinetic profile of controlled release ketoprofen in elderly patients. 1985

M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins

The pharmacokinetics of ketoprofen following the administration of the first and final dose of a controlled release formulation (200 mg ketoprofen) once daily for 10 days to nine elderly patients have been studied. Plasma ketoprofen concentrations were measured by h.p.l.c. The data were compared to previously reported studies in young male volunteers. Mean +/- s.d. peak plasma concentrations (5.6 +/- 1.75 micrograms ml-1 and 6.3 +/- 2.7 micrograms ml-1 on day 1 and day 10, respectively) were higher than those reported in young volunteers given similar treatment, but similar to those reported in young volunteers following 50 mg four times daily of conventionally formulated ketoprofen, and markedly lower than reported following a single 100 mg dose of ketoprofen. The half-life for drug release (mean +/- s.d.) from the controlled release formulation (8.5 +/- 7.4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers. The area under the plasma concentration-time curve was about 65% greater than reported in young volunteers following administration of controlled release ketoprofen. This increase in exposure to ketoprofen is probably partly due to the lower volume of distribution in the elderly and partly due to a reduced renal excretion of the glucuronide metabolite of ketoprofen. It was concluded that controlled release ketoprofen may be administered in standard doses (200 mg once daily) to elderly patients whose elimination processes are not severely impaired (i.e. severe renal failure or hepatic disease).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007660 Ketoprofen An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. Benzoylhydratropic Acid,19,583 RP,2-(3-Benzoylphenyl)propionic Acid,Alrheumat,Alrheumum,Orudis,Profenid,RP-19583,RP 19583,RP, 19,583,RP19583
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010666 Phenylpropionates Derivatives of 3-phenylpropionic acid, including its salts and esters.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
December 1983, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
June 1990, The British journal of clinical practice,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
March 1984, International journal of clinical pharmacology, therapy, and toxicology,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
January 2022, Journal of veterinary pharmacology and therapeutics,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
April 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
January 2009, AAPS PharmSciTech,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
December 1986, British journal of clinical pharmacology,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
January 2010, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
July 1986, Clinical and experimental pharmacology & physiology,
M J Dennis, and P C French, and P Crome, and M Babiker, and J Shillingford, and R Hopkins
January 1992, European journal of clinical pharmacology,
Copied contents to your clipboard!